NasdaqGS:PTCTBiotechs
PTC Therapeutics (PTCT) Huge Q1 Profitability Spike Tests Bullish Earnings Narratives
PTC Therapeutics (PTCT) closed FY 2025 with Q4 revenue of US$164.7 million and a basic EPS loss of US$1.67, alongside net income excluding extra items of a US$135.0 million loss, setting a mixed tone for the year. Over the past six quarters, revenue has ranged from US$196.8 million in Q3 2024 to US$1.2 billion in Q1 2025, while basic EPS has swung from an 11.09 gain in Q1 2025 to losses such as US$1.39 in Q3 2024. This gives investors a wide set of margins to weigh. With the company now...